ArticleBMC cancer2026
Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to generate antibodies against the whole-cell lysate of the AU-565 breast cancer cell line using hybridoma technology and to assess their immunogenic properties and preliminary immunoassay-oriented reactivity. Two adjuvants, Complete Freund's Adjuvant (CFA) and Polyoxidonium (PO), were compared for their ability to enhance immune responses. Cytokine profiling was also performed to evaluate the immunomodulatory effects of antigen-adjuvant formulations.
methodsAU-565 cell lysates were prepared by sonication and combined with CFA or PO. Immunostimulatory activity was evaluated in vitro by nitric oxide (NO) production in J774 macrophages and in vivo by antibody titers in Balb/c mice. Hybridoma cells were generated from splenocytes of immunized mice. Since single-cell cloning was not performed, antibodies were collected from pooled hybridoma cultures, representing a mixture of monoclonal antibodies recognizing multiple epitopes. Cytokine levels (IL-6, IL-12, GM-CSF, and TNF-α) were quantified by ELISA to characterize the inflammatory response pattern induced by the antigen-adjuvant formulations.
resultsThe AU-565 antigen + CFA formulation significantly increased NO production compared with untreated control macrophages and generated the strongest antibody titers compared with the PBS control group. Cytokine profiling showed that the AU-565 antigen + CFA formulation significantly increased IL-12, GM-CSF, and TNF-α secretion compared with untreated control macrophages, indicating a pronounced pro-inflammatory response pattern in the macrophage model, while a moderate IL-6 increase relative to untreated control macrophages suggested partial support for humoral-associated signaling. The hybridoma-derived antibody mixture displayed stronger ELISA reactivity toward AU-565 and MCF-7 lysates than the commercial antibody, indicating broader relative lysate recognition under the assay conditions used.
conclusionThe hybridoma-derived antibody mixture showed strong immunogenicity, cytokine-associated immune stimulation, and preliminary potential for breast cancer-oriented immunoassay development; however, additional validation of specificity and analytical performance is required before diagnostic utility can be concluded. The AU-565 antigen-CFA combination not only enhanced antibody production but also promoted a favorable cytokine profile, underscoring CFA's superiority as an adjuvant in breast cancer-oriented immunogen design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.